Brought to you by 
Daiichi buys Plexxikon for $805mm up front, plus earn-outs
22 Nov 2022
Executive Summary
Daiichi Sankyo Co. Ltd. will pay $805mm in cash to acquire privately held drug discovery company Plexxikon Inc., a move that will greatly expand the Japanese pharmaco's oncology business. The deal has also been sweetened with up to $130mm in launch-related earn-outs based on PLX4032, Plexxikon's lead candidate for malignant melanoma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Daiichi buys Plexxikon for $805mm up front, plus earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice